vTv Therapeutics Inc. - (VTVT): Price and Financial Metrics


vTv Therapeutics Inc. - (VTVT)

Today's Latest Price: $1.75 USD

0.02 (1.16%)

Updated Sep 25 4:00pm

Add VTVT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

VTVT Stock Summary

  • With a price/sales ratio of 5,406.22, vTv Therapeutics Inc has a higher such ratio than 99.8% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, vTv Therapeutics Inc is reporting a growth rate of 264.7%; that's higher than 94.81% of US stocks.
  • As for revenue growth, note that VTVT's revenue has grown -99.78% over the past 12 months; that beats the revenue growth of only 0.47% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to vTv Therapeutics Inc are AUPH, VNRX, AIMT, MRTX, and RVNC.
  • VTVT's SEC filings can be seen here. And to visit vTv Therapeutics Inc's official web site, go to www.vtvtherapeutics.com.
VTVT Daily Price Range
VTVT 52-Week Price Range

VTVT Stock Price Chart Technical Analysis Charts


VTVT Price/Volume Stats

Current price $1.75 52-week high $4.23
Prev. close $1.73 52-week low $1.35
Day low $1.70 Volume 266,943
Day high $1.78 Avg. volume 597,720
50-day MA $2.21 Dividend yield N/A
200-day MA $2.31 Market Cap 124.34M

vTv Therapeutics Inc. - (VTVT) Company Bio


vTv Therapeutics Inc., a biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company was founded in 2015 and is based in High Point, North Carolina.


VTVT Latest News Stream


Event/Time News Detail
Loading, please wait...

VTVT Latest Social Stream


Loading social stream, please wait...

View Full VTVT Social Stream

Latest VTVT News From Around the Web

Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

HIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 …

Benzinga | September 23, 2020

An In-Depth Look At vTv Therapeutics

Pity is the most agreeable feeling among those who have little pride and no prospects of great conquests."― Friedrich Nietzsche Today, we take an in depth look at a small developmental company that comes up from time to time in comments. The stock also sees large purchases of stock by...

The Insiders Forum on Seeking Alpha | September 16, 2020

vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update

HIGH POINT, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended…

GlobeNewswire | August 3, 2020

vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference

HIGH POINT, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Conference (AAIC), held virtually, July 27–31, 2020. The poster presentation will highlight additional analyses of the clinical data from the STEADFAST Study of azeliragon showing the relative contribution of the effects on individual test items, as well as on the higher level cognitive and/or function domains, to the potential benefits of azeliragon on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and Clinical Dementia Rating Scale (CDR), tools used by doctors to assess someone’s Alzheimer’s disease.Details of the virtual presentation are below:Presentation Title: E...

Yahoo | July 27, 2020

vTv Therapeutics' TTP399 successful in mid-stage type 1 diabetes study

VTv Therapeutics (VTVT) is up 45% premarket on the heels of results from the Phase 2 Simplici-T1 study evaluating TTP399 as an adjunct to insulin therapy in adults with type 1 diabetes.The results demonstrate that TTP399, a once-a-day pill, reduces HbA1c and improves time in range, without increasing hypoglycemia or any signal for adverse...

Seeking Alpha | June 15, 2020

Read More 'VTVT' Stories Here

VTVT Price Returns

1-mo -17.45%
3-mo -22.57%
6-mo -7.41%
1-year 19.86%
3-year -70.83%
5-year -72.99%
YTD 2.94%
2019 -35.85%
2018 -55.91%
2017 24.43%
2016 -29.07%
2015 N/A

Continue Researching VTVT

Want to see what other sources are saying about vTv Therapeutics Inc's financials and stock price? Try the links below:

vTv Therapeutics Inc (VTVT) Stock Price | Nasdaq
vTv Therapeutics Inc (VTVT) Stock Quote, History and News - Yahoo Finance
vTv Therapeutics Inc (VTVT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8422 seconds.